Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study

Trial Profile

Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2013

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Coronary artery disease; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms REMS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jul 2013 Planned End Date changed from 1 Mar 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 10 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top